Pfizer's Quiet Cash Comeback: Buy the Dip for a Yield-Backed Re-rate
Pfizer is trading near the top of its 52-week range but still offers a compelling income-plus-upside trade. The combination of roughly $10.4B in annual free cash flow, a 6.3% dividend yield, modest leverage and a developing oral GLP-1 program supports a mid-term re-rating. We lay out an actionable swing trade with entry, stop and target, plus catal…